chrisvoncsefalvay/vaers-outcomes huggingface dataset:
blood clots in his nose; White Spots on the Palm of Hand; allergic reaction; This is a spontaneous report from a contactable consumer (patient). A male patient of unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st single dose for covid-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient was having allergic reaction he did have blood clots in his nose that did go after some days but now he did have white spots on the palms of his hands and he wanted to know if it was like common allergic reaction. Outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
The patient came in and asked for a shot.  We had processed, injected, and reviewed her 4th Covid booster dose.  She called later and stated that she wanted her second shingles shot.  She was due for the booster dose of both.   She stated that she felt sick to her stomach and had lots of body pain on 7/14.  She slept all night and woke up on 7/15 feeling good.  There was still a little pain.    These are normal side effects of the moderna vaccine.  We are uncertain if she had asked for the wrong shot or if we had heard her wrong.  We have reviewed our process and made improvements.
The pt experienced a 5 x 4 x 3.5 cm indurated mass on the right triceps.
dose of Menveo, later received lyophilized menveo with Pfizer diluent; received lyophilized menveo with Pfizer diluent; received lyophilized menveo with Pfizer diluent; This case was reported by a other health professional via call center representative and described the occurrence of overdose in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   Co-suspect products included tozinameran (Covid 19 Vaccine Pfizer) for prophylaxis.   Concomitant products included Men ACWY-CRM NVS (Menveo).   On an unknown date, the patient received Menveo and Covid 19 Vaccine Pfizer at an unknown dose and frequency. On an unknown date, not applicable after receiving Menveo and unknown after receiving Menveo, the patient experienced overdose, wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The action taken with Covid 19 Vaccine Pfizer was unknown. On an unknown date, the outcome of the overdose, wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were reported as follows: The patient received 1 dose of Menveo correctly and 1hr. later received the lyophilized menveo with Pfizer Covid 19 diluent when they were supposed to get the Covid Pfizer due to, which led to overdose , inappropriate dose of vaccine administration and wrong solution used in drug reconstitution. No reactions reported. The reporter consented to follow up. This is 1 of the 12 linked cases, reported by the same reporter.
Fever over 101° and bulging fontanelle. He was sent to hospital after being evaluated at multicare, where they accused me of shaking him instead of taking responsibility for the adverse effects of the vaccines. He had ultrasounds done on his head and got a CT scan at the hospital.
Noticed a swelling/mass in the vagina. Diagnosed with urethral cyst and is recommended to be treated with surgery. Unknown if related to vaccine. Delivered baby vaginally and currently breastfeeding.
Booter Shot, woke up in the middle of night with fever, chills, and headache.
Pt reported feeling dizzy and experienced visual changes while seated about 10 minutes after receiving his first dose. Pt stated that he wanted to check his blood pressure because he felt like it was high. Pt had no medical hx. Pt?s vitals were obtained.  All were within normal limits excluding blood pressure, which was slightly elevated. Pt refused medical care and transport. Pt was advised to call 911 if symptoms worsened. Pt signed AMA paperwork. Pt stated that he felt much better and was comfortable walking to his car with his family.
Itching in 10 minutes followed by reddening of skin and red splotches,  extreme headaches, body aches, fever, sweats, chills, cough, nausau, swelling of lymphs nodes in chest and groin, shortness of breath, and light sensitivity.
Accidentally administered a dose of 0.25mL of the Modern Covid 19 bivalent instead of 0.5mL; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Accidentally administered a dose of 0.25mL of the Modern Covid 19 bivalent instead of 0.5mL) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Accidentally administered a dose of 0.25mL of the Modern Covid 19 bivalent instead of 0.5mL) and NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Accidentally administered a dose of 0.25mL of the Modern Covid 19 bivalent instead of 0.5mL) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Accidentally administered a dose of 0.25mL of the Modern Covid 19 bivalent instead of 0.5mL).    No concomitant products were reported.  This case was regarding one patient.  No treatment drugs were reported.
My arm was very sore for a few days, which is normal. But the shoulder pain never went away and I lost mobility in my left arm.  Made an appointment with Orthopedics May 26th, got Xray. Xray was normal. Was told to return if symptoms persisted. Returned June 23rd. Diagnosed with SIRVA and began physical therapy.
Received MMR II vaccine on Tuesday afternoon, 5/28/2019. No pain at the injection site, no dizziness, nausea or any overall "bad" feelings afterward the shot. Woke up early on Friday morning, 5/31/2019, and as I was getting out of bed, I felt extreme dryness in my right eye. Rubbed my eye and looked in the bathroom mirror at my right eye, which was extremely red. Relived I could not blink or close my right eye. Noticed the wrinkles on the right side of my mouth had changed more to looking like drooping than lines on my face. Maybe 5 minutes later, I was brushing my teeth and went to rinse, which resulted in water spraying out of the right side of my mouth when I tried to spit out the toothpaste and water. I started to freak out about not being able to move, ONLY on the right side. Was able to get a doctor's visit as soon as possible that same Friday morning, 5/31/2019, approximately 7:30am. Doctor ruled out stroke and diagnosed Bell's Palsy. Developed eye infection by Saturday morning, 6/01/2019, due to eye being open,without blinking for about 24 hours. Artificial tears during that 1st 24 hours did nothing to keep my eye wet.
24hrs p/vax pt c/o rt arm pain; swollen arm noticed (excluding hand);notified MD office instructed to apply ice/given APAP q 4 hrs;mom noticed dec in size somewhat w/ice & APAP;
Experienced pain and soreness at injection site for 3 days after injection. The day after injection I was feeling light headed and began to experience several bouts of uncontrollable tremors across my whole body. I have also experienced general chest discomfort and pain since the injection.
pain in the left shoulder; This spontaneous case was reported by a physician and describes the occurrence of ARTHRALGIA (pain in the left shoulder) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     no medical history was reported.  Concomitant products included TOPIRAMATE (TROKENDI), LEVOTHYROXINE SODIUM (SYNTHROID) and CETIRIZINE HYDROCHLORIDE (ZYRTEC R) for an unknown indication.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (pain in the left shoulder). The patient was treated with IBUPROFEN for Shoulder pain, at a dose of unknown; PARACETAMOL (TYLENOL) for Shoulder pain, at a dose of unknown and CORTISONE on 03-Feb-2021 at an unspecified dose and frequency. At the time of the report, ARTHRALGIA (pain in the left shoulder) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication included lathortin.
Erythema multiforme (see attached progress note). History: Patient came today at 6 years of age with complaint of from onset 2 days ago of a slightly itchy rash on both his inner thighs that has now spread to his lower extremities. The patient reports no other signs of illness. He did get immunizations on October 9 specifically the VARIVAX #2, HAVRIX #1 and FLUMIST. Exam: The patient appears to be in no distress. Examination of the skin did show a confluent erythematous irregular slightly raised rash consisting of flat round and oval plaques as well as target lesions on both inner thighs with some scant lesions on the lateral aspects of the thighs as well as the distal lower extremities consistent with erythema multiforme. Assessment: Erythema multiforme following immunizations. Plan: I provided the mother with written and verbal information on erythema multiforme and recommended topical treatments if he does develop more significant itching. A report will be submitted to VAERS. Mother was advised to contact us if the child develops involvement of mucous membranes, eyes or mouth. I advised mother that the cause of this eruption is unclear, including in this case, though it is generally benign and self-limited. Since it did occur after immunizations we will report to VAERS.
Chest pains, sporadic over 5 days.  Center and both sides near center  of chest
pt had janseen for her first dose,  and this is the first pfeizer shot she's gotten, she started getting numbness in her lips and throat started closing in a little.
Patient stated that he had something going on with his eyes as he was reading the lot # to Agent; bad headache; tiredness; muscle ache from the 1st dose has subsided; he felt slightly weaker than normal; muscular weakness in both of his legs; Arm pain in the Left arm where he received the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm pain in the Left arm where he received the vaccine), ASTHENIA (he felt slightly weaker than normal), MUSCULAR WEAKNESS (muscular weakness in both of his legs), OCULAR DISCOMFORT (Patient stated that he had something going on with his eyes as he was reading the lot # to Agent) and HEADACHE (bad headache) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Feb-2021, the patient experienced PAIN IN EXTREMITY (Arm pain in the Left arm where he received the vaccine) and MUSCULAR WEAKNESS (muscular weakness in both of his legs). On an unknown date, the patient experienced ASTHENIA (he felt slightly weaker than normal), OCULAR DISCOMFORT (Patient stated that he had something going on with his eyes as he was reading the lot # to Agent), HEADACHE (bad headache), FATIGUE (tiredness) and MYALGIA (muscle ache from the 1st dose has subsided). On 12-Feb-2021, PAIN IN EXTREMITY (Arm pain in the Left arm where he received the vaccine) had resolved. On 14-Feb-2021, MUSCULAR WEAKNESS (muscular weakness in both of his legs) had resolved. At the time of the report, ASTHENIA (he felt slightly weaker than normal), OCULAR DISCOMFORT (Patient stated that he had something going on with his eyes as he was reading the lot # to Agent), HEADACHE (bad headache) and FATIGUE (tiredness) outcome was unknown and MYALGIA (muscle ache from the 1st dose has subsided) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Action taken with mRNA-1273 in response to the event was not applicable. Treatment information was not provided. Concomitant product use was not provided.   This case was linked to MOD-2021-097274 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: No specific follow-up information recorded. On 10-Jun-2021: Significant follow-up was updated. Suspect dosage information was updated. Adverse Events, Events causality and outcome were updated and previous outcome of event was updated as per information.
8 papules with wide erythematous base on chest, behind ear, scalp, arms, pruritic.
05Apr90 pt vax; exp nausea which resolved in 24 hrs.  12Apr90 devel soreness in salivary glands.  Tx w/ ASA.
The day after receiving the Polio IPV vaccine, my son was biting his hands in frustration and had diarrhea.  At 11:30am on 5/17/19 his daycare called to say he had three diarrhea diapers in an hour. It was very excessive for him.  My son had no fever.  On 5/18/19 my son developed a rash on his  right lower leg.  I am not sure how long it was there, as I discovered it while he was napping.  Patient has had several  diarrhea  episodes that have  resulted in a  green, jello like substance. He has also had many extremely watery poops. No blood has been observed in his stools.  He has been averaging anywhere from 1-5 diarrhea diapers a day. This is not his normal poop routine.  We have taken him to the doctors several times and we were told to wait two weeks before we did any testing. We are now going to test for Lyme disease as well as getting his stool tested.
This case was reported by a healthcare professional and described the occurrence of hive in a 22-month-old female subject who was vaccinated with HAVRIX (GlaxoSmithKline). Concurrent medications included BENADRYL, ZYRTEC and ORAPRED. On 28 March 2011 at 16:00 the subject received 1st dose of HAVRIX at 0.5 ml in the left thigh. On 29 March 2011, 1 day after vaccination with HAVRIX, the subject experienced hive. She was taken to the director's office and was started on steroids. The nurse was going to follow-up with the mother to see how the subject was doing. No additional details were reported. The outcome of the event was not known. Follow-up information was received via the reporter on 27 April 2011. It was reported that the child experienced hives and urticaria one day following administration of HAVRIX on 29 March 2011. The events resolved and were considered to be possibly related to treatment with HAVRIX.
Pt given PNEUMOVAX (L) deltoid 6/23/09. Pt had pain later same day (+) redness of skin. Rash spread (+) tender (-) drainage (+) felt warm (-) chills (-) respiratory issue.
Client passed out and had possible seizure. Client was evaluated by EMS and was offered to be taken to ER but declined.
10-18-2010 Received Influenza vaccine. 10-19-2010 Injection site became red and swollen. 10-20-2010 Dr prescribed antibiotics and ointment.
Redness and swelling and induration approximately 4 cm circular area around vaccine site on right upper outer thigh. With tenderness and fever. It took approximately 1 month to resolve. Small are of discoloration and induration still present after 2 months.
This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52-year-old female patient received BNT162b2 (BNT162B2), on 29Apr2022 as dose 4 (booster), single (Lot number: FJ4989) at the age of 52 years for Covid-19 immunisation; CoviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for Covid-19 immunisation. The patient's relevant medical history included: "Latex" (unspecified if ongoing), notes: latex; "honeydew melon, pineapple" (unspecified if ongoing), notes: honeydew melon, pineapple. Concomitant medication(s) included: PROGESTERONE. Past drug history included: Chlorine, reaction(s): "known allergies: chlorine", notes: known allergies: chlorine. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative. Therapeutic measures were taken as a result of Covid-19, drug ineffective. No follow-up attempts are possible. No further information is expected.
Information has been received from a physician concerning a 44 year old White female who on 12/5/01 at 5:00 pm was vaccinated IM with pneumococcal 23 polyvalent (lot # 640744/0994L). On 12/6/01 at 3:00 pm, the patient developed a fever of 100 degrees F, and an injection site reaction that included erythema to the left deltoid, edema, warmth, and cellulitis. It was also reported that the area was tender to touch. The patient subsequently recovered from the erythema, edema, tenderness, and fever. The outcome of the injection site warmth and cellulitis was unknown. Unspecified medical attention was sought. No further information is expected.
Date the vial was initially stored in the refrigerator 26 Jan 2022,and administered on 03 March 2022.; 7 patients received a Moderna vaccine past the 30 day use by date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (7 patients received a Moderna vaccine past the 30 day use by date) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator 26 Jan 2022,and administered on 03 March 2022.) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 070H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 03-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (7 patients received a Moderna vaccine past the 30 day use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator 26 Jan 2022,and administered on 03 March 2022.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (7 patients received a Moderna vaccine past the 30 day use by date) and PRODUCT STORAGE ERROR (Date the vial was initially stored in the refrigerator 26 Jan 2022,and administered on 03 March 2022.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported. The vial was initially stored in the refrigerator on 26 Jan 2022. No treatment medication were reported.
This non-serious spontaneous case, initially received on 05-Feb-2018 from other health professional, concerning a 35-year-old, adult male patient. It was reported that, the FLUCELVAX was exposed to temps above 8C (reported as first excursion). Later the temperature of the refrigerator was dropped to -0.01C and was out of range for about 8.5 hours which was the second excursion. On 22-Jan-2018, the patient was administered with FLUCELVAX QIV (batch number: 195125, expiry date: 30-Apr-2018, dose, route of administration, anatomical location: not reported) (stored out of recommended conditions). The reporter assessed the events as non-serious.
On the day of the vaccine 3/30/2021, that afternoon I noticed a slight difficulty breathing. I was unable to take a full breath of air. I took it easy the rest the afternoon. I woke up the next day and it was gone.  Around lunch time, I started to feel dizzy and felt like I was going to fall over.  The nurse took my BP and it was 140/90.  Around 2:30pm, my face was sweaty and flushing. My pressure became super low 120/70. I went home and started to notice difficulty breathing .  The next day, I woke up totally fine- no breathing difficulty and bp  normal.  I went to work.  Around lunch time, started having high blood pressure 142/100.  I went to the doctor and the doctor adjusted my blood pressure medications.  About a week later, I noticed tinnitus in my ears for 2 days and woke up and it went away.  I also experienced visual light sensitivity and needed extra time to adjust to light changes.  I also felt constant fatigue.  About 12 days, all symptoms resolved.
Two day following administration of the Flumist, soldier developed pharyngitis, sinusitis.  Tx'd by another provider for bacterial sinusitis which soldier reports decrease ssx but still loses his voice if he has to shout at his troops c/o S/T in a.m.
p/vax pt exposed to a neighbor friend who totally broke out on 5/17/98 exp a severe bout of gastroenteritis & a temp;
Fatigue, chills and headache then pain and swelling in left armpit as well as extreme skin sensitivity to cold surfaces and cold water.
No other AE reported; "a pediatric patient was given a dose of 25U of adult VAQTA.; Inappropriate preparation of medication; This spontaneous report was received from a physician and refers to a pediatric patient of unknown gender. No information regarding the patient's medical history, concurrent conditions and concomitant medications was provided. On 08-MAR-2021, the patient was vaccinated with an adult dose of hepatitis a vaccine, inactivated (VAQTA) 0.5 ml (25 U) from the adult dose, lot # T014590 with expiration date on 15-APR-2021 (route of administration was unknown) for prophylaxis. The administering nurse drew up 1 ml of adult hepatitis a vaccine, inactivated (VAQTA) then wasted 0. 5 ml of the adult hepatitis a vaccine, inactivated (VAQTA). No adverse event was reported.
RECEIVED VAC ON 1/27. ON 2/7 PATIENT STARTED EXPERIENCING VISUAL DISTURBANCES /KALIDOSCOPIC VISION WITH COLORS & SHAPES MORPHING INTO OTHER SHAPES  RIGHT IN HIS FIELD OF VISION WHEREBY HE IS WALKING INTO DOORWAYS, MISCALCULATING SPACE, SPILLING ETC. THESE SYMPTOMS  ARE CONTINUING AS OF 2/18. HE SAW PCP,, OPTHAMOLOGY, A RETINA SPECIALIST, HAD COMPREHENSIVE LAB BATTERY, VASCULAR TESTING & MRI, ALL OF  WHICH DID NOT REVEAL ETIOLOGY FOR SYMPTOMS.
not feeling well; This is a spontaneous report from a Pfizer-sponsored program COVAX US Support. A contactable consumer (patient) reported that a female patient of unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot/batch number and expiration date not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient was scheduled today (07Apr2021) for the second dose. Patient was sent home from work today (07Apr2021) since she was not feeling well. Patient wanted to know if she could still have the vaccine even if she was not feeling well. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.